Bio-Techne (TECH) EBITDA (2009 - 2026)

Bio-Techne has reported EBITDA for 18 years, with the latest figure at $46.5 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 77.71% year-over-year to $46.5 million; the trailing twelve-month figure through Mar 2026 stood at $124.8 million (changed 0.13% YoY), and the FY2025 full-year result was $91.8 million, down 41.08% from the prior year.
• EBITDA for Q1 2026 stood at $46.5 million, up from $40.1 million in the prior quarter.
• The five-year high for EBITDA was $83.0 million in Q2 2023, with the low at $4.5 million in Q2 2025.
• Average EBITDA over 5 years is $45.2 million, with a median of $41.5 million recorded in 2022.
• Peak annual rise in EBITDA reached 329.51% in 2025, while the deepest fall reached 88.04% in 2025.
• Tracing TECH's EBITDA over 5 years: stood at $66.7 million in 2022, then tumbled by 37.29% to $41.8 million in 2023, then sank by 77.7% to $9.3 million in 2024, then jumped by 329.51% to $40.1 million in 2025, then rose by 16.16% to $46.5 million in 2026.
• The last three EBITDA figures came in at $46.5 million (Q1 2026), $40.1 million (Q4 2025), and $33.7 million (Q3 2025), per Business Quant data.

Peer Comparison